Candriam S.C.A. Abb Vie Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Abb Vie Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 387,222 shares of ABBV stock, worth $65.7 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

387,222

Previous 232,481 66.56%

Holding current value

$65.7 Million

Previous $39.9 Million 91.77%

% of portfolio

0.45%

Previous 0.25%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$163.84 - $199.33 $25.4 Million - $30.8 Million	154,741 Added 66.56%	387,222 $76.5 Million
Q2 2024 Aug 05, 2024	SELL	$154.79 - $180.76 $1.86 Million - $2.17 Million	-12,005 Reduced 4.91%	232,481 $39.9 Million
Q1 2024 May 03, 2024	BUY	$159.82 - $182.1 $3.81 Million - $4.34 Million	23,834 Added 10.8%	244,486 $44.5 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $1.22 Million - $1.37 Million	8,839 Added 4.17%	220,652 $34.2 Million
Q3 2023 Nov 13, 2023	SELL	$133.59 - $154.65 $450,465 - $521,479	-3,372 Reduced 1.57%	211,813 $31.6 Million
Q2 2023 Aug 08, 2023	BUY	$132.51 - $164.9 $2.06 Million - $2.57 Million	15,561 Added 7.8%	215,185 $29 Million
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $7.31 Million - $8.42 Million	-50,552 Reduced 20.21%	199,624 $31.8 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $9.67 Million - $11.6 Million	-69,902 Reduced 21.84%	250,176 $40.5 Million
Q3 2022 Nov 10, 2022	SELL	$134.21 - $153.93 $1.57 Million - $1.8 Million	-11,723 Reduced 3.53%	320,078 $43 Million
Q2 2022 Aug 03, 2022	SELL	$137.62 - $174.96 $3.86 Million - $4.91 Million	-28,037 Reduced 7.79%	331,801 $50.8 Million
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $2.24 Million - $2.78 Million	16,981 Added 4.95%	359,838 $58.3 Million
Q4 2021 Feb 10, 2022	SELL	$107.43 - $135.93 $851,919 - $1.08 Million	-7,930 Reduced 2.26%	342,857 $46.4 Million
Q3 2021 Nov 09, 2021	SELL	$106.4 - $120.78 $113,741 - $129,113	-1,069 Reduced 0.3%	350,787 $37.8 Million
Q2 2021 Jul 20, 2021	SELL	$105.21 - $117.21 $18.8 Million - $20.9 Million	-178,225 Reduced 33.62%	351,856 $39.6 Million
Q1 2021 Apr 29, 2021	BUY	$102.3 - $112.62 $1,432 - $1,576	14 Added 0.0%	530,081 $54.6 Million
Q4 2020 Jan 22, 2021	SELL	$80.49 - $108.67 $10.9 Million - $14.8 Million	-135,741 Reduced 20.39%	530,067 $56.8 Million
Q3 2020 Oct 19, 2020	BUY	$85.91 - $100.83 $192,266 - $225,657	2,238 Added 0.34%	665,808 $58.3 Million
Q2 2020 Jul 23, 2020	SELL	$73.37 - $98.18 $5.76 Million - $7.7 Million	-78,451 Reduced 10.57%	663,570 $65.2 Million
Q4 2019 Jan 21, 2020	SELL	$72.13 - $90.25 $8.81 Million - $11 Million	-122,092 Reduced 14.13%	742,021 $66,000
Q3 2019 Oct 21, 2019	BUY	$62.98 - $75.72 $20.1 Million - $24.2 Million	318,994 Added 58.52%	864,113 $65,000
Q2 2019 Aug 01, 2019	SELL	$65.7 - $83.98 $1.41 Million - $1.8 Million	-21,394 Reduced 3.78%	545,119 $39.5 Million
Q1 2019 May 02, 2019	BUY	$77.14 - $90.79 $1.48 Million - $1.74 Million	19,159 Added 3.5%	566,513 $45.7 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $2.1 Million - $2.59 Million	26,953 Added 5.18%	547,354 $50.5 Million
Q3 2018 Nov 07, 2018	BUY	$88.91 - $98.84 $712,791 - $792,400	8,017 Added 1.56%	520,401 $49.2 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $16.2 Million - $19.2 Million	180,525 Added 54.4%	512,384 $47.5 Million
Q1 2018 May 09, 2018	BUY	$92.01 - $123.21 $4.6 Million - $6.16 Million	50,033 Added 17.75%	331,859 $31.4 Million
Q4 2017 Feb 07, 2018	BUY	$89.56 - $98.21 $5.77 Million - $6.33 Million	64,410 Added 29.63%	281,826 $27.3 Million
Q3 2017 Nov 03, 2017	BUY	$69.85 - $89.22 $15.2 Million - $19.4 Million	217,416	217,416 $19.3 Million

Others Institutions Holding ABBV

# of Institutions

3,837

Shares Held

1.25B

Call Options Held

15.7M

Put Options Held

11.3M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account